Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279890 · ClinicalTrials.gov registry record · Phase 1
Topical Agent for Treatment of Red Skin
A Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00279890 is a Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00279890, a Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety
Conditions Studied
Interventions
- DRUG Topical SR-01
Study Locations (1)
Arizona
- Mayo Clinic - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279890
The ClinicalTrials.gov registry entry for NCT00279890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Topical SR-01 is the first listed.
NCT00279890 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT00279890 about?
NCT00279890 is a clinical study titled "Topical Agent for Treatment of Red Skin". SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety
What is the current status of trial NCT00279890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-07. Estimated completion is 2007-01.
What conditions does trial NCT00279890 study?
This clinical trial studies the following conditions: Rosacea, Bilaterally Symmetric Red Skin on Cheeks.
What interventions are being tested in trial NCT00279890?
The interventions under investigation include: Topical SR-01 (DRUG).
Who is sponsoring clinical trial NCT00279890?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00279890 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
-
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.